Core Viewpoint - The company has corrected prior accounting errors in accordance with relevant accounting standards and regulations, ensuring that the financial statements more accurately reflect its financial position and operating results [1][3][4]. Summary by Sections 1. Reasons for Correction - The company received an administrative regulatory decision from the China Securities Regulatory Commission, which identified non-compliance in financial accounting practices, prompting a thorough self-examination and subsequent adjustments to the financial reports [1][2]. 2. Impact on Financial Statements - The adjustments resulted in a reduction of operating revenue by 4.5468 million RMB, operating costs by 1.1034 million RMB, and sales expenses by 0.3512 million RMB. Additionally, other current assets increased by 1.1034 million RMB, while other current liabilities rose by 4.1955 million RMB. The adjustments also included transferring 382.1245 million RMB to fixed assets and 185.8157 million RMB to investment properties, along with an increase in accumulated depreciation by 9.5472 million RMB [2]. 3. Review Procedures - The Audit Committee and Board of Directors reviewed the correction process, agreeing that it complied with relevant accounting standards and regulations, and concluded that the revised financial data provides a more objective and fair representation of the company's financial status [3][4]. 4. Other Remarks - The company expressed sincere apologies for any inconvenience caused to investors due to the corrections and emphasized its commitment to improving financial oversight, training for financial personnel, and enhancing internal controls to prevent future issues [5].
广东丸美生物技术股份有限公司关于前期会计差错更正的公告